These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22246202)

  • 1. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.
    Venkataraman S; Alimova I; Tello T; Harris PS; Knipstein JA; Donson AM; Foreman NK; Liu AK; Vibhakar R
    J Neurooncol; 2012 May; 107(3):517-26. PubMed ID: 22246202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
    Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
    Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
    Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
    Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases expression in atypical teratoid rhabdoid tumors.
    Sredni ST; Halpern AL; Hamm CA; Bonaldo Mde F; Tomita T
    Childs Nerv Syst; 2013 Jan; 29(1):5-9. PubMed ID: 23143003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
    Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
    Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
    Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
    Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
    Wetmore C; Boyett J; Li S; Lin T; Bendel A; Gajjar A; Orr BA
    Neuro Oncol; 2015 Jun; 17(6):882-8. PubMed ID: 25688119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
    Weingart MF; Roth JJ; Hutt-Cabezas M; Busse TM; Kaur H; Price A; Maynard R; Rubens J; Taylor I; Mao XG; Xu J; Kuwahara Y; Allen SJ; Erdreich-Epstein A; Weissman BE; Orr BA; Eberhart CG; Biegel JA; Raabe EH
    Oncotarget; 2015 Feb; 6(5):3165-77. PubMed ID: 25638158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
    Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
    Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
    Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
    Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
    Knipstein JA; Birks DK; Donson AM; Alimova I; Foreman NK; Vibhakar R
    Neuro Oncol; 2012 Feb; 14(2):175-83. PubMed ID: 22156471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
    Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
    Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.
    Torchia J; Golbourn B; Feng S; Ho KC; Sin-Chan P; Vasiljevic A; Norman JD; Guilhamon P; Garzia L; Agamez NR; Lu M; Chan TS; Picard D; de Antonellis P; Khuong-Quang DA; Planello AC; Zeller C; Barsyte-Lovejoy D; Lafay-Cousin L; Letourneau L; Bourgey M; Yu M; Gendoo DMA; Dzamba M; Barszczyk M; Medina T; Riemenschneider AN; Morrissy AS; Ra YS; Ramaswamy V; Remke M; Dunham CP; Yip S; Ng HK; Lu JQ; Mehta V; Albrecht S; Pimentel J; Chan JA; Somers GR; Faria CC; Roque L; Fouladi M; Hoffman LM; Moore AS; Wang Y; Choi SA; Hansford JR; Catchpoole D; Birks DK; Foreman NK; Strother D; Klekner A; Bognár L; Garami M; Hauser P; Hortobágyi T; Wilson B; Hukin J; Carret AS; Van Meter TE; Hwang EI; Gajjar A; Chiou SH; Nakamura H; Toledano H; Fried I; Fults D; Wataya T; Fryer C; Eisenstat DD; Scheinemann K; Fleming AJ; Johnston DL; Michaud J; Zelcer S; Hammond R; Afzal S; Ramsay DA; Sirachainan N; Hongeng S; Larbcharoensub N; Grundy RG; Lulla RR; Fangusaro JR; Druker H; Bartels U; Grant R; Malkin D; McGlade CJ; Nicolaides T; Tihan T; Phillips J; Majewski J; Montpetit A; Bourque G; Bader GD; Reddy AT; Gillespie GY; Warmuth-Metz M; Rutkowski S; Tabori U; Lupien M; Brudno M; Schüller U; Pietsch T; Judkins AR; Hawkins CE; Bouffet E; Kim SK; Dirks PB; Taylor MD; Erdreich-Epstein A; Arrowsmith CH; De Carvalho DD; Rutka JT; Jabado N; Huang A
    Cancer Cell; 2016 Dec; 30(6):891-908. PubMed ID: 27960086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
    Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
    Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
    Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor.
    Giang LH; Wu KS; Lee WC; Chu SS; Do AD; Changou CA; Tran HM; Hsieh TH; Chen HH; Hsieh CL; Sung SY; Yu AL; Yen Y; Wong TT; Chang CC
    J Exp Clin Cancer Res; 2023 Dec; 42(1):346. PubMed ID: 38124207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.